Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study
Authors' conclusion
iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24 weeks.
Study context
- Population
- Adults ≥18 years with T2D on premixed insulin for ≥3 months and <10 years, ± 1–2 oral antidiabetic drugs (OADs), HbA1c ≥7.5% to ≤10.0%; 89.5% switched from twice-daily premixed insulin; mean diabetes duration 15.7 (SD 8.3) years
- Participants
- 162 adults
- Comparison
- Switch from premixed insulin to iGlarLixi
- iGlarLixin = 162
- Outcome
- Change in HbA1c from baseline
- Follow-up
- Week 24
Methodological detailsphase 4, 24-week
- Phase 4
- 24-week
Main finding
As reported in the abstract
Change in HbA1c from baseline (baseline mean 8.5%)
iGlarLixi
1.2
Least squares (LS) mean reduction · 95% CI −1.4–-1.1 · %
Secondary outcomes
HbA1c <7% achieved · Week 24
- Participants achieving HbA1c target <7%
- 37.6% (95% CI: 30.0, 45.7)
Change in body weight from baseline · Week 24
- LS mean body weight change
- −1.0 kg (95% CI: −1.6, −0.5)
Change in fasting and post-prandial plasma glucose from baseline · Week 24
mg/dL
- Fasting plasma glucose decrease
- 45.6 (SD ± 52.4)
- Post-prandial plasma glucose decrease
- 67.6 (SD ± 65.1)
Safety
- Confirmed symptomatic hypoglycaemia
- 38.3%
- ADA level 1
- 35.8%
- ADA level 2
- 15.4%
- ADA level 3
- 0.0%
Original publication
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study. Diabetes Obes Metab. Published 17 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →